BioSpace News Archive

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy ® .

Treace Medical Concepts, Inc. today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced that Andrew Brenner, M.D., Ph.D. has formally joined the Company in a part-time capacity.

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentation of the 2024 American Association for Cancer Research (AACR) Annual Meeting.

InMode Ltd. announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thursday, May 2, 2024.

Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter ended February 29, 2024.

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.

Numinus Wellness Inc. will release its financial results for the quarter ended February 29, 2024.